Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare ... ( SOUTH SAN FRANCISCO Calif. May 16...)

Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference

Date:5/16/2008

SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Citi Investment Research Global Healthcare Conference in New York City on May 22, 2008 at 9:30 a.m. EDT.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational ... to come and make a difference in the Tampa Bay ... check to provide the support needed to keep the science ... transform the IMAX Dome Theatre from film to a state-of-the-art ... Dome Theatre in the state of Florida, and it is ...

(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...

(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...

(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...

(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...

Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2 Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3 Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4 Health News:Human Brain Has Coping Mechanism for Dehydration 2 Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2 Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2 Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3 Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2 Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3 Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4 Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5

[0] Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI)[0] Human Brain Has Coping Mechanism for Dehydration [0] Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed [0] North York Dental Provides Services to Toronto Children in Light of Growing Demand [0] Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening

... http://www.cryocath.com , Toronto Stock Exchange Symbol: CYT, ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced ... Selected Third Quarter Financial and Operational Highlights: ... $9.2 million or a 12.0% increase over ...

... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...

... Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... third quarter ended June 30, 2008. The,Company will host ... am,eastern time (details follow below)., The Company reported ... $19.0 million or $0.25 per share for the quarter ...

... IRVINE, Calif., Aug. 5 SectorWatch.biz announces the,availability ... release of,articles and message boards relative to the ... aforementioned equities and the,opportunity for investors to respond ... can view MarketStats by visiting: http://www.SectorWatch.biz ,-a ...

... Goodison goes for gold and aims to give back to Mercy Ships ... ... European Laser Champion and one of Britain,s greatest medal hopes at the ... seagoing charity Mercy Ships which provides free medical care to the people ...

... age management practice, announced the opening of Cenegenics Indiana. ... leader is launching over 2008-2009. The new Cenegenics Indiana ... The center,s established protocols and personalized programs for healthy ... Minutes, 20/20, Nightline and GQ. , ...

CryoCath Announces Fiscal 2008 Third Quarter Results Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF Olympic Sailing Hopeful Backs Hospital Ship Charity Global Leader In Age Management Announces New Indiana Medical Center

(Date:7/24/2014)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014. The ... the Food and Drug Administration (FDA) had approved Zalviso. ... notification to the company from the FDA regarding the ...

(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014 PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...

(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...

Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2 QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2 QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3 QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4 QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5

[0] AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso [0] PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2014 Financial Results [0] QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen

... Volcano Corporation (Nasdaq: VOLC ), a ... tools designed to enhance the diagnosis and treatment of ... reached an agreement with Fukuda Desnhi Co., Ltd. to ... This transaction follows the successful transition of its distribution ...

... platform presentation at the 46th annual meeting of the ... Stockholm, investigators for Biodel Inc. (Nasdaq: BIOD ... evaluating a new pH-neutral formulation of Linjeta™ (VIAject®). ... Germany) and colleagues reported that the new pH-neutral, 100 ...

Cached Medicine Technology:Volcano Announces It Will End Distribution Agreement with Fukuda; Transition Enhances Company's Direct Selling Program in Japan 2 Volcano Announces It Will End Distribution Agreement with Fukuda; Transition Enhances Company's Direct Selling Program in Japan 3 Volcano Announces It Will End Distribution Agreement with Fukuda; Transition Enhances Company's Direct Selling Program in Japan 4 Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 2 Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting 3

Volcano Announces It Will End Distribution Agreement with Fukuda; Transition Enhances Company's Direct Selling Program in Japan Results of Linjeta™ Study Versus Insulin Lispro Reported Today in Platform Presentation at EASD Annual Meeting

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

Medicine Products:

Benztropine, Urine Beryllium, Serum or Plasma Benzodiazepines Bendylate